【摘要】 本文评论顺铂和卡铂之后的第三代铂抗癌药物的研究状况。报道其配合物的抗肿瘤活性、限量毒性、交叉耐药性和其中四种配合物的Ⅱ期临床结果。这些配合物的总体水平并不优于顺铂和卡铂。研究抗癌机理与顺铂和卡铂不同的新型铂配合物是增加该类药物的抗肿瘤活性和克服交叉耐药性的途径之一。更多还原

【Abstract】 The studies and clinical applications on the third generation platinum anticancer drugs following Cisplatin and Carboplatin have been reviewed in details.The antitumor activities,dose-limiting toxicities and cross-resistances of several Pt complexes which have entered into phase I clinical trials and phase II clinical of 4 of them are reported.It is indicated that the total levels of these complexes are not superior to Cisplatin and Carboplatin.Investigation on novel Pt complexes with different anticancer’s mechanisms from Cisplatin and Carboplatin is one of ways to increase the anticancer activities of Pt drugs and to overcome their cross-resistances.更多还原